📣 VC round data is live. Check it out!
- Public Comps
- IDEXX Laboratories
IDEXX Laboratories Valuation Multiples
Discover IDEXX Laboratories' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Siemens Healthineers, Wuxi AppTec, Agilent, Waters and more.
IDEXX Laboratories Overview
About IDEXX Laboratories
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Founded
1983
HQ

Employees
11.0K
Website
Sectors
Financials (LTM)
EV
$44B
Valuation Multiples
Start free trialIDEXX Laboratories Financials
IDEXX Laboratories reported last 12-month revenue of $4B and EBITDA of $2B.
In the same LTM period, IDEXX Laboratories generated $3B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
IDEXX Laboratories P&L
In the most recent fiscal year, IDEXX Laboratories reported revenue of $4B and EBITDA of $2B.
IDEXX Laboratories is profitable as of last fiscal year, with gross margin of 62%, EBITDA margin of 35%, and net margin of 25%.
Financial data powered by Morningstar, Inc.
IDEXX Laboratories Stock Performance
IDEXX Laboratories has current market cap of $43B, and enterprise value of $44B.
Market Cap Evolution
IDEXX Laboratories' stock price is $550.82.
IDEXX Laboratories share price decreased by 2.3% in the last 30 days, and increased by 2.7% in the last year.
IDEXX Laboratories has an EPS (earnings per share) of $13.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44B | $43B | -2.8% | -2.3% | -2.0% | 2.7% | $13.43 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIDEXX Laboratories Valuation Multiples
IDEXX Laboratories trades at 9.9x EV/Revenue multiple, and 28.0x EV/EBITDA.
EV / Revenue (LTM)
IDEXX Laboratories Financial Valuation Multiples
As of June 3, 2026, IDEXX Laboratories has market cap of $43B and EV of $44B.
IDEXX Laboratories has a P/E ratio of 39.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IDEXX Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


IDEXX Laboratories Margins & Growth Rates
IDEXX Laboratories grew revenue by 9% and EBITDA by 12% in the last fiscal year.
In the most recent fiscal year, IDEXX Laboratories reported gross margin of 62%, EBITDA margin of 35%, and net margin of 25%.
IDEXX Laboratories Margins
IDEXX Laboratories Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
IDEXX Laboratories Operational KPIs
IDEXX Laboratories' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
IDEXX Laboratories' Rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IDEXX Laboratories' Rule of X is 59% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
IDEXX Laboratories Competitors
IDEXX Laboratories competitors include Siemens Healthineers, Wuxi AppTec, Agilent, Waters, Edwards Lifesciences, Roper Technologies, Alcon, IQVIA, Veeva and DexCom.
Most IDEXX Laboratories public comparables operate across Medical Devices, Laboratory Services, Healthcare Software, BioTech, DeepTech, B2B SaaS, HealthTech and Vertical SaaS.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.6x | 1.6x | 7.9x | 7.9x | |||
| 5.9x | 5.6x | 9.7x | 11.3x | |||
| 5.7x | 5.5x | 19.8x | 18.8x | |||
| 13.2x | 9.2x | 36.8x | 27.2x | |||
| 7.8x | 7.5x | 26.2x | 24.4x | |||
| 5.6x | 5.4x | 13.9x | 13.6x | |||
| 3.4x | 3.3x | 13.1x | 12.9x | |||
| 2.7x | 2.6x | 11.6x | 11.4x | |||
This data is available for Pro users. Sign up to see all IDEXX Laboratories competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by IDEXX Laboratories
IDEXX Laboratories has acquired 2 companies to date.
Last acquisition by IDEXX Laboratories was on August 22nd 2022. IDEXX Laboratories acquired TECTA-PDS for undisclosed valuation.
Latest Acquisitions by IDEXX Laboratories
| Description | TECTA-PDS is a Blacksburg, Virginia-based manufacturer of automated microbiological water monitoring systems approved by the US EPA. Its PDS 1000M analyzer detects coliforms and E. coli in drinking water within 15 hours using laser-based detection, deployed in utilities across North America and Europe. | ezyVet is a New Zealand-headquartered cloud-based practice management software for veterinary clinics worldwide. Founded in 2006 in Palmerston North, the platform handles appointments, inventory, billing, and patient records for over 5,000 practices across 80 countries. ezyVet integrates with diagnostic tools like Idexx and supports multi-location chains with real-time dashboards. The system features mobile apps for vets and clients, telemedicine modules, and compliance with standards in the US, UK, and Australia. It processes millions of transactions annually, emphasizing scalability from solo practices to corporate groups. |
| HQ Country | ||
| HQ City | Toronto | Auckland |
| Deal Date | 22 Aug 2022 | 2 Jun 2021 |
| Valuation | undisclosed | $157M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all IDEXX Laboratories acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IDEXX Laboratories
| When was IDEXX Laboratories founded? | IDEXX Laboratories was founded in 1983. |
| Where is IDEXX Laboratories headquartered? | IDEXX Laboratories is headquartered in United States. |
| How many employees does IDEXX Laboratories have? | As of today, IDEXX Laboratories has over 11K employees. |
| Who is the CEO of IDEXX Laboratories? | IDEXX Laboratories' CEO is Jonathan J. Mazelsky. |
| Is IDEXX Laboratories publicly listed? | Yes, IDEXX Laboratories is a public company listed on Nasdaq. |
| What is the stock symbol of IDEXX Laboratories? | IDEXX Laboratories trades under IDXX ticker. |
| When did IDEXX Laboratories go public? | IDEXX Laboratories went public in 1991. |
| Who are competitors of IDEXX Laboratories? | IDEXX Laboratories main competitors include Siemens Healthineers, Wuxi AppTec, Agilent, Waters, Edwards Lifesciences, Roper Technologies, Alcon, IQVIA, Veeva, DexCom. |
| What is the current market cap of IDEXX Laboratories? | IDEXX Laboratories' current market cap is $43B. |
| What is the current revenue of IDEXX Laboratories? | IDEXX Laboratories' last 12 months revenue is $4B. |
| What is the current revenue growth of IDEXX Laboratories? | IDEXX Laboratories revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of IDEXX Laboratories? | Current revenue multiple of IDEXX Laboratories is 9.9x. |
| What is the current EBITDA of IDEXX Laboratories? | IDEXX Laboratories' last 12 months EBITDA is $2B. |
| What is IDEXX Laboratories' EBITDA margin? | IDEXX Laboratories' last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of IDEXX Laboratories? | Current EBITDA multiple of IDEXX Laboratories is 28.0x. |
| What is the current FCF of IDEXX Laboratories? | IDEXX Laboratories' last 12 months FCF is $1B. |
| What is IDEXX Laboratories' FCF margin? | IDEXX Laboratories' last 12 months FCF margin is 25%. |
| What is the current EV/FCF multiple of IDEXX Laboratories? | Current FCF multiple of IDEXX Laboratories is 40.3x. |
| How many companies IDEXX Laboratories has acquired to date? | As of June 2026, IDEXX Laboratories has acquired 2 companies. |
| What was the largest acquisition by IDEXX Laboratories? | $157M acquisition of ezyVet on 2nd June 2021 was the largest M&A IDEXX Laboratories has done to date. |
| In how many companies IDEXX Laboratories has invested to date? | IDEXX Laboratories hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to IDEXX Laboratories
Lists including IDEXX Laboratories
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

